Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)

Aim Non‐alcoholic fatty liver disease (NAFLD), a hepatic manifestation of metabolic syndrome, is associated with an increased risk of developing lifestyle‐related diseases including type 2 diabetes, cardiovascular disease and cerebral vessel disease. No current drug therapy provides the ideal effect...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Hepatology research 2015-03, Vol.45 (3), p.269-278
Hauptverfasser:	Eguchi, Yuichiro, Kitajima, Yoichiro, Hyogo, Hideyuki, Takahashi, Hirokazu, Kojima, Motoyasu, Ono, Masafumi, Araki, Norimasa, Tanaka, Kenichi, Yamaguchi, Miyuki, Matsuda, Yayoi, Ide, Yasushi, Otsuka, Taiga, Ozaki, Iwata, Ono, Naofumi, Eguchi, Takahisa, Anzai, Keizo
Format:	Artikel
Sprache:	eng
Schlagworte:	fatty liver glucagon-like peptide-1 liraglutide non-alcoholic fatty liver disease non-alcoholic steatohepatitis steatohepatitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!